The 2026 outlook for fisher and paykel stock remains a focal point for New Zealand investors as the healthcare giant enters a phase of significant earnings acceleration and strategic market expansion. Currently trading on the NZX under the ticker FPH, the company has recently upgraded its FY26 guidance, projecting a record operating revenue of approximately $2.30 billion and a net profit after tax (NPAT) between $450 million and $470 million. This bullish trajectory is supported by a 14% increase in first-half revenue and a robust 39% surge in net profit, driven primarily by strong demand in its Hospital product segment and favorable currency tailwinds from a shifting NZD:USD exchange rate.
- Current Valuation: Market capitalization stands at approximately $22.82 billion NZD as of March 2026.
- Dividend Outlook: A projected annual dividend of $0.60 per share, with the next payment expected in July 2026.
- Analyst Sentiment: Consensus price targets hover around $40.91, suggesting potential for further capital growth.
- Key Growth Driver: "LiDAR 2.0" and the transition to software-centric respiratory care are enhancing margins.
Current Valuation: Market capitalization stands at approximately $22.82 billion NZD as of March 2026.
Dividend Outlook: A projected annual dividend of $0.60 per share, with the next payment expected in July 2026.
Analyst Sentiment: Consensus price targets hover around $40.91, suggesting potential for further capital growth.
Key Growth Driver: "LiDAR 2.0" and the transition to software-centric respiratory care are enhancing margins.
<div><img src="https://newzealand-finance.nz/wp-content/uploads/2026/03/fisher-and-paykel-stock-performance.jpg"></div>
Understanding fisher and paykel stock in the current nz market
The resilience of fisher and paykel stock in 2026 is a testament to the company's ability to navigate global trade complexities, including recent US tariff pressures on New Zealand-sourced hospital products. Despite a 75-basis point impact from these tariffs, the bank has managed to expand its gross margin to 63.0%, largely through manufacturing efficiencies and the successful rollout of new technologies like the Airvo 3. For local investors, the stock serves as a defensive yet growth-oriented asset, often outperforming broader NZX indices during periods of economic volatility due to its essential healthcare nature.
- Hospital Revenue: Grew by 17% in the first half of FY26, reaching $692.2 million.
- Homecare Expansion: Latest OSA masks and home respiratory devices contributed to a 10% segment growth.
- R&D Commitment: Sustained investment at 11% of revenue to maintain market leadership.
- Global Reach: Revenue is diversified across the US (42%), Europe (27%), and Asia-Pacific (21%).
Hospital Revenue: Grew by 17% in the first half of FY26, reaching $692.2 million.
Homecare Expansion: Latest OSA masks and home respiratory devices contributed to a 10% segment growth.
R&D Commitment: Sustained investment at 11% of revenue to maintain market leadership.
Global Reach: Revenue is diversified across the US (42%), Europe (27%), and Asia-Pacific (21%).
| Key Metric | FY26 Updated Guidance | Previous Guidance |
| Operating Revenue | ~$2.30 Billion | $2.17 – $2.27 Billion |
| Net Profit (NPAT) | $450M – $470M | $410M – $460M |
| Gross Margin | 63.5% (Forecast) | 63.0% (Actual H1) |
| Capital Expenditure | ~$225 Million | Unchanged |
The role of currency tailwinds in valuation
A critical factor for fisher and paykel stock performance this year has been the fluctuation of the New Zealand dollar against the US dollar. The company's updated guidance assumes an exchange rate of roughly 60 cents, which has provided a meaningful boost to reported earnings compared to the 57-cent assumption used previously. As an export-heavy entity, Fisher & Paykel Healthcare is highly sensitive to these movements; a weaker NZD typically makes its global sales more valuable when repatriated, supporting the high Price-to-Earnings (P/E) ratio of 53.3x currently seen by the market.
Strategic growth and clinical practice change
The long-term value of fisher and paykel stock is increasingly tied to its success in shifting clinical practice within global hospitals. The company isn't just selling hardware; it's promoting high-flow therapy as a standard of care for respiratory distress. This "razor and blade" model—where the sale of a device leads to recurring revenue from high-margin consumables—is the primary engine for the 19% projected compound annual growth rate (CAGR) in net income through 2029. This strategic shift reduces the impact of seasonal respiratory cycles, providing a more predictable income stream for shareholders.
Manufacturing efficiency and margin expansion
Operational leverage is becoming a major theme for fisher and paykel stock in 2026. The construction of the fifth building at the East Tamaki campus in Auckland is a physical manifestation of this growth, designed to centralize R&D and manufacturing to drive further cost-saving "continuous improvement" activities. By internalizing more of its supply chain and optimizing production for its new mask ranges, the company has managed to increase its operating margin by 335 basis points, even as it faces rising logistics costs.
- Free Cash Flow: Reached $173.2 million for the half-year ending September 2025.
- Net Cash Position: Improved to $237.8 million, allowing for organic reinvestment.
- Gearing Ratio: Remains healthy at -13.5%, indicating low debt reliance.
- Tariff Mitigation: Ongoing efforts to shift sourcing or secure refunds for US tariffs.
Free Cash Flow: Reached $173.2 million for the half-year ending September 2025.
Net Cash Position: Improved to $237.8 million, allowing for organic reinvestment.
Gearing Ratio: Remains healthy at -13.5%, indicating low debt reliance.
Tariff Mitigation: Ongoing efforts to shift sourcing or secure refunds for US tariffs.
<div><img src="https://newzealand-finance.nz/wp-content/uploads/2026/03/fisher-and-paykel-manufacturing-facility.jpg"></div>
Dividend stability and shareholder returns
For many Kiwi income investors, fisher and paykel stock represents one of the most reliable dividend payers in the healthcare sector. The company has a 19-year history of uninterrupted payments, a track record that provides comfort during market downturns. In December 2025, the bank paid an interim dividend of 19.0 cents per share, which was fully imputed for New Zealand tax purposes. Looking ahead to the final payment for FY26, analysts expect a slight increase to roughly 33 cents, bringing the total annual yield to approximately 1.5%. While this yield is lower than some NZX "yield plays," it is backed by a conservative payout ratio of 58%.
| Dividend Event | Amount (NZD) | Date | Status |
| Interim Dividend | $0.19 | Dec 16, 2025 | Paid |
| Final Dividend | $0.26 (Prev) | Jul 04, 2025 | Paid |
| Estimated Next | $0.33 | Jul 03, 2026 | Forecast |
| Total Annual | $0.60 | 2026 Total | Forecast |
Comparison with healthcare sector peers
When evaluating fisher and paykel stock, it is useful to compare its performance against global and regional peers like ResMed and Cochlear. While ResMed trades at a lower P/E of roughly 21.9x, Fisher & Paykel’s premium 53x multiple is often justified by its higher return on equity (ROE) of 22.56% and its dominant 19% share in the specialized respiratory humidification market. The New Zealand-based company has shown superior revenue growth (10.6% vs market 4.3%) and a cleaner balance sheet, making it a "quality leader" in the eyes of many institutional funds. Read more in Wikipedia.
Analyst price targets and market sentiment
The consensus among the 12 primary analysts covering fisher and paykel stock has shifted significantly since the guidance upgrade in February 2026. The average 12-month price target is now $40.91, with the most bullish forecasts reaching as high as $48.30. This optimistic sentiment is driven by the belief that the "tariff drag" is already priced in, and that the market is underestimating the growth potential of the Airvo 3 and F&P Nova nasal masks in European markets. However, bearish analysts point to the current high valuation as a "tight gap" for new entries, suggesting that any miss in second-half hospitalizations could lead to a sharp correction.
- Alpha Spread High: $48.30 NZD.
- Simply Wall St Fair Value: $40.81 NZD.
- Morningstar Rating: 3-Star (Fair Value).
- Consensus Rating: Moderate Buy.
Alpha Spread High: $48.30 NZD.
Simply Wall St Fair Value: $40.81 NZD.
Morningstar Rating: 3-Star (Fair Value).
Consensus Rating: Moderate Buy.
Risks to the bull case for fph stock
No investment is without risk, and fisher and paykel stock faces several unique challenges in the 2026-2027 window. The most immediate is "respiratory season severity"—if the Northern Hemisphere experiences an unusually mild winter, the volume of hospital consumables sold will likely fall short of the high-end guidance. Additionally, the expiry of Section 122 tariff exemptions in July 2026 could introduce new cost pressures if a permanent resolution isn't reached. Finally, the ongoing high interest rate environment in New Zealand continues to provide competition for capital, as fixed-income assets offer attractive yields compared to the 1.5% provided by FPH dividends.
<div><img src="https://newzealand-finance.nz/wp-content/uploads/2026/03/fisher-and-paykel-respiratory-device.jpg"></div>
Institutional and insider ownership trends
Ownership structure provides a telling story for fisher and paykel stock. Institutional investors hold approximately 70% of the float, reflecting the stock's status as a "must-own" for large NZ and Australian funds. While there was some minor insider selling reported in February 2026, it was largely attributed to personal tax obligations rather than a lack of confidence in the firm's direction. The recent entry of several large ESG-focused global funds has also provided a new floor for the share price, as Fisher & Paykel Healthcare scores highly on sustainability metrics relative to its medical device peers.
| Ownership Group | Percentage | Recent Trend |
| Institutions | ~70% | Increasing (ESG Funds) |
| Retail (Individual) | ~25% | Stable |
| Insiders/Directors | < 5% | Slight Trimming |
The impact of r&d and new product launches
The "pipeline" is the lifeblood of fisher and paykel stock. In FY26, the launch of the F&P Nova Nasal mask in Europe and the hosting of over 100 clinical forums globally have been the primary catalysts for capturing new market share in the homecare segment. These forums are designed to educate doctors on the benefits of humidified high-flow therapy, effectively building a future customer base for the company's consumables. With R&D spending forecasted to grow at 14% per annum, the company is ensuring that its next generation of devices will be ready to replace legacy models by late 2027.
Technical analysis and trading ranges
Looking at the price action of fisher and paykel stock, the $38.00 to $41.00 range has emerged as a significant zone of support and resistance. In early March 2026, the stock hit a high of $41.40 before settling near $38.35. Technical indicators suggest the stock is currently in a "cooling off" period after the 11% rally following the February earnings upgrade. For traders, a break above $42.00 could signal a push toward the all-time highs of 2021, while a drop below $35.00 would suggest that the market is becoming concerned about the sustainability of the 2026 earnings beat.
- 52-Week High: $41.40 NZD.
- 52-Week Low: $31.80 NZD.
- RSI (14-Day): 56.5 (Neutral).
- Moving Average (200-Day): $34.75 NZD.
52-Week High: $41.40 NZD.
52-Week Low: $31.80 NZD.
RSI (14-Day): 56.5 (Neutral).
Moving Average (200-Day): $34.75 NZD.
Future outlook: what to expect in 2027
As we move toward the close of the 2026 financial year, the trajectory for fisher and paykel stock appears strong. The company's focus on "sustainable profitable growth" is yielding results, with earnings per share (EPS) expected to grow by 13.4% annually through 2028. If the bank can successfully manage the July tariff transition and maintain its 63% gross margin, it is well-positioned to hit the $2.5 billion revenue milestone by early 2027. For the patient investor, Fisher & Paykel remains a cornerstone of the New Zealand healthcare sector, offering a rare combination of global scale and local innovation.
Final thoughts on fisher and paykel stock
In summary, fisher and paykel stock remains a high-quality investment for those seeking exposure to the global medical technology sector via the NZX. The combination of upgraded 2026 guidance, strong margin expansion, and a robust pipeline of new respiratory products outweighs the short-term risks associated with currency volatility and trade tariffs. While the current valuation is demanding, the company's ability to consistently outgrow its market and deliver fully imputed dividends makes it a resilient choice for long-term wealth creation in a New Zealand-focused portfolio.
fisher and paykel stock faq
Is fisher and paykel stock a good buy in 2026
Analysts generally view the stock as a "Hold" or "Moderate Buy" following its recent price rally, with a consensus target of $40.91.
What is the current share price of fisher and paykel healthcare
As of mid-March 2026, the stock is trading around $38.35 NZD on the NZX.
Does fph stock pay dividends
Yes, Fisher & Paykel Healthcare pays semi-annual dividends, with an annual total of approximately $0.60 expected for 2026.
What was the fph revenue guidance for fy26
The company recently upgraded its FY26 revenue guidance to approximately $2.30 billion NZD.
Are the dividends for fisher and paykel healthcare imputed
Yes, dividends for New Zealand shareholders are typically fully imputed, providing tax benefits.
What is the ticker symbol for fisher and paykel healthcare
The stock trades under the ticker symbol FPH on both the NZX and the ASX.
Who is the ceo of fisher and paykel healthcare
The current Managing Director and CEO is Lewis Gradon.
What are the main risks for fisher and paykel stock
Key risks include seasonal fluctuations in hospitalizations, US trade tariffs, and NZD/USD exchange rate volatility.
How much market share does fph have in respiratory humidification
Fisher & Paykel is a global leader in hospital-use humidifiers and holds a significant portion of the global market share.
When is the next dividend payment date for fph
The next dividend is estimated to be paid on July 3, 2026, for shareholders of record in late June.
